{"title": "First-in-class type 2 diabetes treatment Glyxambi\u00ae (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies", "author": null, "url": "https://www.fiercepharma.com/pharma-asia/first-class-type-2-diabetes-treatment-glyxambi%C2%AE-empagliflozin-linagliptin-tablets-for", "hostname": "fiercepharma.com", "description": "New dual inhibitor SGLT2/DPP-4 combination therapy offers improved glycemic control as an adjunct to diet and exercise RIDGEFIELD, Conn.< | New dual inhibitor SGLT2/DPP-4 combination therapy offers improved glycemic control as an adjunct to diet and exercise RIDGEFIELD, Conn.", "sitename": "FiercePharma", "date": "2015-03-31", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}